Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Ltd’s stock declined to a fresh 52-week low of Rs.3967 on 20 Jan 2026, marking a significant downturn amid a broader market correction. The stock has underperformed its sector and benchmark indices, reflecting ongoing pressures on valuation and profitability metrics.

Sanofi Consumer Healthcare India Ltd’s share price has fallen to a new all-time low of Rs. 3,967, marking a significant downturn amid sustained negative returns and underperformance relative to key market indices and sector peers.

Sanofi Consumer Healthcare India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 28 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sanofi Consumer Healthcare India Ltd’s stock declined to a fresh 52-week low of Rs.4017 on 19 Jan 2026, marking a significant milestone in its recent price trajectory amid broader market fluctuations and company-specific performance factors.

Sanofi Consumer Healthcare India Ltd’s stock reached a new all-time low of Rs. 4,017 on 19 Jan 2026, marking a significant milestone in its ongoing decline. Despite a slight rebound today, the stock remains under pressure, reflecting a challenging period for the company within the Pharmaceuticals & Biotechnology sector.

Sanofi Consumer Healthcare India Ltd’s stock declined to a fresh 52-week low of Rs 4,285 on 9 Jan 2026, marking a significant price level that reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and broader market indices over the past year, signalling a period of subdued investor sentiment and valuation adjustments.

Sanofi Consumer Healthcare India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 28 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Sanofi Consumer Healthcare India Ltd has reached a new 52-week low, with its stock price touching Rs 4344 today. This marks a significant decline amid broader market fluctuations and company-specific performance trends.

Sanofi Consumer Healthcare India Ltd has recently touched a 52-week low, closing near Rs 4,360.3, marking a significant decline in its stock price amid broader sector and market dynamics. The stock’s performance over the past year has been notably weaker compared to benchmark indices, reflecting a combination of valuation concerns and profit contraction.

Sanofi Consumer Healthcare India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 28 Oct 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 29 December 2025, providing investors with the most up-to-date analysis.

Sanofi Consumer Healthcare India has reached a 52-week low, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector. The stock's recent price movement highlights a notable shift in its market valuation, with the share price touching its lowest level in the past year.

Sanofi Consumer has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment. The recent assessment highlights a complex interplay of strong financial trends, valuation concerns, and technical indicators that have shaped the stock’s current market standing.

Sanofi Consumer Healthcare India is exhibiting a shift in technical momentum, with recent evaluation adjustments signalling a bearish trend across multiple timeframes. The stock’s price action and key technical indicators suggest a cautious outlook as it navigates resistance levels and market pressures within the Pharmaceuticals & Biotechnology sector.

Sanofi Consumer Healthcare India has experienced a notable shift in its technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent price movements and technical indicators suggest a nuanced change in the stock’s trend, warranting close attention from investors and market analysts alike.

Sanofi Consumer has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters including valuation, financial trends, technical outlook, and quality metrics. This adjustment comes amid a backdrop of subdued stock performance and sector-specific pressures within the Pharmaceuticals & Biotechnology industry.

Sanofi Consumer Healthcare India reported strong financial results for the quarter ending September 2025, achieving record net sales of Rs 233.90 crore and a profit before tax of Rs 81.10 crore. The company demonstrated resilience in the pharmaceuticals sector despite experiencing stock volatility and market fluctuations.

Sanofi Consumer Healthcare India Ltd. reported a strong performance in Q2 FY26, with net profit reaching ₹62.90 crores, marking a sequential increase of 3.62% from Q1 FY26's ₹60.70 crores and an impressive year-on-year surge of 39.78% from ₹45.00 crores in Q2 FY25. The company, with a market capitalisation of ₹11,151.43 crores, continues to demonstrate operational resilience despite trading at elevated valuations. However, the stock has faced headwinds, declining 2.90% to ₹4,842.00 following the results announcement, reflecting investor concerns about premium pricing and technical weakness.